Skip to main content
Explore URMC
menu

IBRT17055 / BBI-DSP7888-201G / Nimish Mohile

Research Question:
Does the drug DSP-7888 help patients with glioblastoma?

Basic Study Information

Purpose:
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.

Location: University of Rochester Medical Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Nimish Mohile

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search